Reversal of Botulinum Neurotoxin Injection Related Dysphonia With Pyridostigmine

• Status: Recruiting
• Trial end date: 2022-06-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to evaluate the effects of pyridostigmine (Mestinon) on patient vocal outcomes after undergoing laryngeal botulinum neurotoxin (BoNT) injections, which is a standard treatment for spasmodic dysphonia. Pyridostigmine (Mestinon) has been used for treatment of BoNT overdose, and it is our hope that it will be beneficial in the management of post BoNT breathy phase.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Eastern Virginia Medical School
• Treatments: Bromides; Pyridostigmine Bromide

Criteria

Inclusion Criteria:

• Males and Females Aged 21-100

• Scheduled for Botulinum Neurotoxin (BoNT) Treatment for Spasmodic Dysphonia (SD)

Exclusion Criteria:

• Subjects who are Pregnant or Lactating

• Subjects with Compromised Renal or Cardiac Function

• Subjects with Spasmodic Dysphonia with Superimposed Vocal Tremor